PGEN vs QURE Stock Comparison
PGEN currently leads QURE in this stock comparison, with AIQ scores of 55 vs 39. The clearest difference is value.
What is the main difference between PGEN and QURE?
PGEN leads the current stock comparison as Precigen, Inc., with the clearest separation coming from value and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
Precigen, Inc. vs uniQure N.V.
PGEN leads
PGEN leads by 16 AIQ points, primarily on Value and Quality.
Competitive: 4 of 6 evidence groups support PGEN, and its current signal state is conflicted.
Precigen, Inc.
uniQure N.V.
The Algovestiq AIQ Score currently favors PGEN over QURE, 55 versus 39 as of Nov 15, 2026. PGEN's advantage is driven primarily by stronger value and quality. PGEN also shows the weaker technical structure relative to its 50-day moving average. 4 of 6 covered evidence groups favor PGEN today, and the comparison is rated Competitive on stability: the leader is throwing conflicting signals. PGEN lead: Stable — the AIQ differential has held near 16 points over 30 sessions.
Compare Precigen, Inc. and uniQure N.V. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Price return from daily closes; distributions are not included.
Price return comparison
Growth of $10,000, price only
Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.
Compare PGEN and QURE against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Value63 vs 38PGEN +25
- Quality60 vs 42PGEN +18
- Momentum55 vs 41PGEN +14
- Risk Resilience31 vs 31Even
4 of 6 evidence groups favor PGEN. PGEN’s edge is concentrated in value and quality.
What changed since the last close
Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.
No factor moved materially.
New signals
- ADX Trend Strengthening — neutral, trend, medium horizon
- Keltner Channel Breakdown — bearish, volatility, short horizon
Largest factor move: Quality +1, not enough on its own to move the overall score.
New signals
- Death Cross Active — bearish, trend, long horizon (0.48%)
- Downtrend Structure Active — bearish, trend, long horizon
- Low Volume Rally Warning — bearish, volume, short horizon (0.71x)
PGEN's lead widened by 1 AIQ point in the latest session.
Deeper signal detail for each name lives on its own signals page — PGEN and QURE both carry a full feed there.
The central trade-off
PGEN (Precigen, Inc.): the stronger current systematic profile, led by value and quality.
QURE (uniQure N.V.): the counter-case, on technicals.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
PGENPGEN on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
PGENPGEN on combined revenue and EPS growth.
Value
PGENPGEN on the peer-relative Value factor, by 25 points.
Momentum
PGENPGEN on the Momentum factor, by 14 points.
Lower downside
QUREQURE carries the lower 1-month annualized volatility.
Analyst upside
PGENPGEN on implied upside to the consensus price target.
AIQ vs Wall Street
Where the systematic read and the analyst consensus line up — and where they do not.
| Measure | PGEN | QURE | Note |
|---|---|---|---|
| Implied upside to target | +164.3% | +110.7% | PGEN has more room |
| Target dispersion | 0% | +93.7% | Lower is tighter analyst agreement |
| Consensus | Buy | Buy | Context, not a primary driver |
| Analysts covering | 4 | 13 | Higher coverage generally improves confidence |
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
4 of 6 covered evidence groups favor PGEN. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | PGEN | 55 vs 39 |
| Fundamentals | PGEN | revenue growth 34.9% vs -11%; EPS growth 66.7% vs 27.9%; TTM ROE 42.7% vs -20.8%; gross margin 91% vs 29.3%; operating margin 21.4% vs -10.2% |
| Valuation | PGEN | Value 63 vs 38 |
| Technicals | QURE | Price vs 50-day -32.6% vs -19.3%; vs 200-day -14% vs -19.7% |
| Risk Resilience | Even | Risk Resilience 31 vs 31 |
| Analyst expectations | PGEN | Target upside 164.3% vs 110.7% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of PGEN and QURE and are excluded from the count.
AIQ Decision Stability
The two are close enough that your objective, not the score, should decide.
- The AIQ gap is wide at 16 points. (supports the conclusion holding)
- The lead has been steady session to session. (supports the conclusion holding)
- The leader is throwing conflicting signals. (argues the conclusion is provisional)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on PGEN.
How the comparison changed
120 daily snapshots · May 27 – Nov 13PGEN lead: Stable — the AIQ differential has held near 16 points over 30 sessions.
- Today
- PGEN +16
- 55 vs 39
- 7 sessions ago
- PGEN +22
- 62 vs 40
- 30 sessions ago
- PGEN +17
- 61 vs 44
- 90 sessions ago
- PGEN +2
- 58 vs 56
The lead changed hands once in this window, most recently on Aug 4 when PGEN moved ahead of QURE.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
1 bullish / 2 bearish / 2 neutral, conflicted
Only PGEN
- Golden Cross Active — bullish, trend, long horizon (27.69%)
- ADX Trend Strengthening — neutral, trend, medium horizon
- Keltner Channel Breakdown — bearish, volatility, short horizon
0 bullish / 4 bearish / 1 neutral
Only QURE
- Death Cross Active — bearish, trend, long horizon (0.48%)
- Downtrend Structure Active — bearish, trend, long horizon
- Low Volume Rally Warning — bearish, volume, short horizon (0.71x)
Both carry 2 more signals that do not separate them: ATR Expansion - Breakout Mode, Beta Spike Warning.
PGEN leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Price is down while the AIQ Score moved up 1 points over the same session — price and model disagree (price -2.58%, AIQ +1 points).
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -3.33%, AIQ 0 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1QURE closes the Value gap — currently 25 points behind, the largest single contributor to PGEN's edge.
- 2QURE's Death Cross Active resolves — a bearish trend rule currently active against it.
- 3PGEN's conflicting signal state resolves bearish — it currently carries 1 bullish and 2 bearish rules at once.
- 4A market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
PGEN leads on balance| Metric | PGEN | QURE |
|---|---|---|
| Revenue growth (YoY) | 34.9% | -11% |
| EPS growth (YoY) | 66.7% | 27.9% |
| Gross margin | 91% | 29.3% |
| Operating margin | 21.4% | -10.2% |
| Return on equity (TTM) | 42.7% | -20.8% |
| Debt to equity | 1.18 | 0.21 |
Performance
PGEN leads 4 of 6 windows| Metric | PGEN | QURE |
|---|---|---|
| 1 week (5 sessions) | 1.6% | 9.7% |
| 1 month (20 sessions) | -28.9% | 9.3% |
| 3 months (63 sessions) | -30.7% | -50.4% |
| 6 months (126 sessions) | 2.7% | -12% |
| Year to date | 8.6% | -0.5% |
| 1 year (252 sessions) | 12.9% | -20.9% |
Technicals
QURE has the stronger structure| Metric | PGEN | QURE |
|---|---|---|
| RSI (14) | 34.2 | 45.7 |
| ADX (14) | 28.8 | 25.3 |
| Price vs 50-day | -32.6% | -19.3% |
| Price vs 200-day | -14% | -19.7% |
| Volatility (1M, annualized) | 127% | 78.5% |
Risk
Split| Metric | PGEN | QURE |
|---|---|---|
| Beta | 1.62 | 0.68 |
| Sharpe ratio | 0.57 | 0.39 |
| Sortino ratio | 0.87 | 0.68 |
| Max drawdown | -50.7% | -70.2% |
| Current drawdown | -47% | -53.4% |
| Annualized volatility | 85.4% | 132.3% |
| Value at risk (95%) | -7.2% | -7.7% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, PGEN or QURE?
On the Algovestiq AIQ Score, PGEN is the stronger of the two as of Nov 15, 2026, scoring 55 against QURE's 39. The edge comes from value and quality. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is PGEN or QURE the better buy right now?
PGEN carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Competitive — 4 of 6 covered evidence groups agree. A Competitive rating means the two are close enough that your objective, not the score, should decide.
Why does the AIQ Score favor PGEN over QURE?
The composite weights Quality, Value, Momentum and Risk Resilience. PGEN leads Value by 25 points; PGEN leads Quality by 18 points; PGEN leads Momentum by 14 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, PGEN or QURE?
Analyst price targets imply +164.3% upside for PGEN and +110.7% for QURE, so the Street currently favors PGEN. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, PGEN or QURE?
PGEN is the better-valued of the two on the peer-relative Value factor. PGEN on the peer-relative Value factor, by 25 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, PGEN or QURE?
PGEN on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, PGEN or QURE?
PGEN on the Momentum factor, by 14 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, PGEN or QURE?
QURE is the more resilient of the two, so the other name carries the higher downside risk. QURE carries the lower 1-month annualized volatility. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is PGEN more profitable than QURE?
PGEN leads on the comparable margin measures — gross margin 91% vs 29.3%; operating margin 21.4% vs -10.2%; ttm roe 42.7% vs -20.8%.
Is PGEN's lead over QURE getting stronger or weaker?
PGEN lead: Stable — the AIQ differential has held near 16 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has changed hands once in that window, most recently on 2026-08-04, when PGEN moved ahead of QURE.
What would change the PGEN vs QURE verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: QURE closes the Value gap — currently 25 points behind, the largest single contributor to PGEN's edge; QURE's Death Cross Active resolves — a bearish trend rule currently active against it; PGEN's conflicting signal state resolves bearish — it currently carries 1 bullish and 2 bearish rules at once; a market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.
What do the current signals say about PGEN and QURE?
PGEN: 1 bullish / 2 bearish / 2 neutral, conflicted. QURE: 0 bullish / 4 bearish / 1 neutral. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on PGEN is Golden Cross Active (bullish, long horizon). On QURE it is Death Cross Active (bearish, long horizon).
Compare PGEN and QURE with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.